MA28400B1 - Derives de pyrazolo [1,5-a] pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase - Google Patents

Derives de pyrazolo [1,5-a] pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase

Info

Publication number
MA28400B1
MA28400B1 MA29182A MA29182A MA28400B1 MA 28400 B1 MA28400 B1 MA 28400B1 MA 29182 A MA29182 A MA 29182A MA 29182 A MA29182 A MA 29182A MA 28400 B1 MA28400 B1 MA 28400B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
pyrimidin
treatment
protein kinase
amine derivatives
Prior art date
Application number
MA29182A
Other languages
English (en)
Inventor
Guido Bold
Andreas Floersheimer
Pascal Furet
Patricia Imbach
Keiichi Masuya
Joseph Schoepfer
Georg Martiny-Baron
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34807167&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28400(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28400B1 publication Critical patent/MA28400B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29182A 2004-01-22 2006-07-10 Derives de pyrazolo [1,5-a] pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase MA28400B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53822004P 2004-01-22 2004-01-22

Publications (1)

Publication Number Publication Date
MA28400B1 true MA28400B1 (fr) 2007-01-02

Family

ID=34807167

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29182A MA28400B1 (fr) 2004-01-22 2006-07-10 Derives de pyrazolo [1,5-a] pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase

Country Status (17)

Country Link
EP (1) EP1708710A1 (fr)
JP (1) JP2007519662A (fr)
KR (1) KR20070009546A (fr)
CN (1) CN1909908A (fr)
AR (1) AR049769A1 (fr)
AU (1) AU2005205915B2 (fr)
BR (1) BRPI0507071A (fr)
CA (1) CA2552885A1 (fr)
EC (1) ECSP066718A (fr)
IL (1) IL176737A0 (fr)
MA (1) MA28400B1 (fr)
NO (1) NO20063758L (fr)
PE (1) PE20051089A1 (fr)
RU (1) RU2006130003A (fr)
TN (1) TNSN06226A1 (fr)
TW (1) TW200528103A (fr)
WO (1) WO2005070431A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) * 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en) * 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1931676B1 (fr) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
ES2403206T3 (es) 2005-12-23 2013-05-16 Ariad Pharmaceuticals, Inc. Compuestos bicíclicos de heteroarilo
JP2009529054A (ja) * 2006-03-08 2009-08-13 ノバルティス アクチエンゲゼルシャフト 神経障害の処置におけるピラゾロ［１，５ａ］ピリミジン−７−イルアミン誘導体の使用
WO2007109183A2 (fr) * 2006-03-20 2007-09-27 Novartis Ag Mutations et polymorphismes de la tyrosine kinase 1 liée au fms
GB0606805D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic compounds
GB0606804D0 (en) * 2006-04-04 2006-05-17 Novartis Ag Organic Compounds
CN101516888A (zh) * 2006-09-28 2009-08-26 诺瓦提斯公司 吡唑并[1,5-a]嘧啶衍生物及其治疗用途
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
EP1918291A1 (fr) * 2006-10-30 2008-05-07 Novartis AG Dérives de pyrazole fusionnes substitués de 3-aminocarbonyle comme modulateurs de protéine kinase
JP5198562B2 (ja) * 2007-06-07 2013-05-15 メルク・シャープ・アンド・ドーム・コーポレーション 置換−３−アミノピラゾールの合成
WO2010118207A1 (fr) 2009-04-09 2010-10-14 Schering Corporation Dérivés pyrazolo[1, 5-a]pyrimidine en tant qu'inhibiteurs de mtor
WO2011041152A1 (fr) 2009-09-30 2011-04-07 Schering Corporation Nouveaux composés inhibiteurs d'erk
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
BR112012029405B1 (pt) 2010-05-20 2021-01-05 Array Biopharma Inc. compostos macrocíclicos como inibidores de trk quinase, composição farmacêutica, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação de um composto
KR101856266B1 (ko) * 2010-08-09 2018-05-09 가부시키가이샤 에누비 켄코우겡큐쇼 카세인 키나아제 1δ 및 카세인 키나아제 1ε 저해제
WO2012023143A1 (fr) 2010-08-19 2012-02-23 E. I. Du Pont De Nemours And Company Pyrazoles fongicides
EP2615916B1 (fr) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
KR101404151B1 (ko) * 2011-11-25 2014-06-05 가톨릭대학교 산학협력단 안과 질환의 예방 및 치료용 약학 조성물
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
EP3322706B1 (fr) 2015-07-16 2020-11-11 Array Biopharma, Inc. Composés substitués de pyrazolo[1,5-a]pyridines comme inhibiteurs de la kinase ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
CN106588893A (zh) * 2016-12-01 2017-04-26 北京万全德众医药生物技术有限公司 维拉佐酮双氧化物的制备
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087578C (fr) 2018-01-18 2023-08-08 Array Biopharma Inc. Composes de pyrazolo[3,4-d]pyrimidine substitues utilises en tant qu'inhibiteurs de la kinase ret
CA3087972C (fr) 2018-01-18 2023-01-10 Array Biopharma Inc. Composes de pyrazolyl[4,3-c]pyridine substitues utilises en tant qu'inhibiteurs de la kinase ret
CA3087354C (fr) 2018-01-18 2023-01-03 Array Biopharma Inc. Composes de pyrrolo[2,3-d]pyrimidines substitues utilises en tant qu'inhibiteurs de la kinase ret
JP7377207B2 (ja) 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
KR20200116481A (ko) * 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
CN109836428A (zh) * 2019-02-27 2019-06-04 华东师范大学 具有免疫抑制活性的吡唑[4,3-d]嘧啶衍生物及用途
EP3996736A4 (fr) * 2019-07-10 2023-05-24 Musc Foundation for Research Development Peptides d'endostatine pour le traitement de tumeurs, d'une fibrose et d'une lésion pulmonaire aiguë
PH12022551282A1 (en) 2019-11-25 2023-11-29 Amgen Inc Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use
WO2023154282A1 (fr) * 2022-02-08 2023-08-17 Theras, Inc. Composés ayant une structure t formée par au moins quatre cycles destinés à être utilisés dans le traitement du cancer et d'autres indications
CN114751910B (zh) * 2022-05-17 2023-02-24 重庆文理学院 一种可诱导细胞巨泡式死亡的化合物及其制备方法和应用
CN117843642A (zh) * 2022-10-09 2024-04-09 麦科萨药业(苏州)有限公司 一种双官能化合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
AU651986B2 (en) * 1991-04-22 1994-08-11 Otsuka Pharmaceutical Factory, Inc. Pyrazolo{1,5-a}pyrimidine derivative and anti-inflammatory containing the same
JP3163413B2 (ja) * 1994-06-21 2001-05-08 株式会社大塚製薬工場 鎮痛剤
EP0714898B1 (fr) * 1994-06-21 2001-11-14 Otsuka Pharmaceutical Factory, Inc. DERIVE DE PYRAZOLO [1,5-a]PYRIMIDINE
WO1998010590A1 (fr) * 1996-09-02 1998-03-12 Sony Corporation Dispositif et procede de transmission d'un signal video
CN1694705A (zh) * 2002-09-04 2005-11-09 先灵公司 用作依赖细胞周期蛋白激酶抑制剂的吡唑并嘧啶
AU2003268385B2 (en) * 2002-09-04 2006-12-21 Pharmacopeia, Inc. Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
CA2552885A1 (fr) 2005-08-04
AU2005205915A1 (en) 2005-08-04
ECSP066718A (es) 2006-10-31
WO2005070431A1 (fr) 2005-08-04
PE20051089A1 (es) 2006-01-25
KR20070009546A (ko) 2007-01-18
JP2007519662A (ja) 2007-07-19
NO20063758L (no) 2006-10-23
AU2005205915B2 (en) 2009-05-21
EP1708710A1 (fr) 2006-10-11
TW200528103A (en) 2005-09-01
BRPI0507071A (pt) 2007-06-19
RU2006130003A (ru) 2008-04-10
TNSN06226A1 (en) 2007-12-03
AR049769A1 (es) 2006-09-06
CN1909908A (zh) 2007-02-07
IL176737A0 (en) 2006-10-31

Similar Documents

Publication Publication Date Title
MA28400B1 (fr) Derives de pyrazolo [1,5-a] pyrimidin-7-yl-amine destines a etre utilises dans le traitement de maladies dependantes de la proteine kinase
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
WO2005123048A3 (fr) Methodes de criblage
EP1465854A4 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
EP1850658A4 (fr) Modalities ameliorees permettant de traiter les maladies degeneratives de la retine
EP1796467A4 (fr) Inhibiteurs imidazo{4,5-b}pyrazinone de proteines kinases
PL2004653T3 (pl) 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy
PL1603915T3 (pl) Podstawione pochodne 8-pirydynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu i 8-pirymidynylo-dihydrospiro-cykloalkilo-pirymido-1,2-a-pirymidyn-6-onu oraz ich zastosowanie przeciwko chorobom neurodegeneracyjnym
NO20041142L (no) Subsitituerte 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyrimidinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater for neurodegenerative lidelser
ATE516037T1 (de) Topische formulierung von ivermectin zur behandlung von dermatologischen erkrankungen
IS7444A (is) Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
IL187900A0 (en) Derivatives of pyrido[2,3-d] pyrimidine, the preparation thereof, and the therapeutic application of the same
MY136822A (en) Derivatives of [6, 7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of cams and leukointegrins
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
WO2007027233A3 (fr) Derives d'acide 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonique
HK1097743A (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
FR2835254B1 (fr) Derives de thiazoles dans le traitement de maladies neurologiques
ZA200050690B (en) Use of modulators of the signal transduction pathway via the protein kinase fyn in the treatment of tumor diseases
AU2003299206A8 (en) Protein complexes involved in neurological diseases
PL371269A1 (en) 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, the use thereof for producing drugs used in the treatment of immunological diseases
SI1663244T1 (sl) Pteridinski derivati za zdravljenje bolezni, povezanih s TNF-alfa
EP1773371A4 (fr) La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau